đź“‹ Part of our complete series: Welding Fumes Assessment Australia: The Complete Guide
Manganese in Welding Fumes: Health Risks & Assessment in Australia
Manganese (Mn) is one of the most insidious hazards in welding fumes, yet many Australian workplaces remain unaware of its neurological consequences. Unlike the well-publicized carcinogenic risks of chromium and nickel in stainless steel welding, manganese exposure leads to manganism—a progressive neurological disease that irreversibly damages the central nervous system. The condition mimics Parkinson’s disease in its early stages but develops through occupational exposure, not age-related degeneration. SafeWork Australia and the Australian Institute of Occupational Hygienists (AIOH) recognize manganese as a serious health risk requiring dedicated assessment and control strategies. For more information, see our guide to chemical hazards and workplace exposure standards.
Since 18 January 2024, the Australian Work Environment Standard (WES) for manganese has been strictly 0.1 mg/m³ as an 8-hour time-weighted average—a stringent limit reflecting the severity of neurological harm. This article examines manganese sources in welding, health risks, assessment methodologies, and control hierarchies to help Australian PCBUs, safety managers, and HSE professionals protect their workforce.
Understanding Manganese in Welding Processes
Sources of Manganese in Welding Fumes
Manganese enters welding fumes from two primary sources: the consumables (electrode, wire, flux) and the base metals being welded. Most modern electrodes and wires contain manganese as an alloying element to improve strength and hardness of the weld deposit. Flux-cored arc welding (FCAW) electrodes are particularly high in manganese; some formulations contain 2–4% manganese by weight. Stainless steel electrodes, despite their association with chromium risks, often contain elevated manganese levels—sometimes 5–8% or higher. Manual metal arc welding (SMAW) rods, especially those used for structural steel and high-strength applications, contribute significant manganese to the fume.
The base metal also contributes. Alloy steels, manganese-hardened steels, and austenitic stainless steels contain inherent manganese. When heated to welding temperatures, this manganese vaporises and condenses into respirable particulates in the fume plume. Low-manganese welding processes are technically feasible but uncommon in Australian industry; few manufacturers actively market “low-Mn” consumables despite the health imperative.
{{IMAGE_BODY_1}}
Welding Processes with Highest Manganese Exposure
FCAW and SMAW generate the highest manganese fume concentrations. Field studies consistently show that FCAW welders can exceed the 0.1 mg/m³ WES within minutes of starting work, even in moderately ventilated workshops. SMAW electrode selection dramatically affects exposure: high-tensile structural electrodes produce 40–60% higher manganese fumes than mild steel electrodes. Submerged arc welding (SAW) is often overlooked as a manganese hazard because fume is visually minimal; however, manganese concentration in the fume can be elevated, making SEG exposure assessment essential. Learn more about fumes from thermal cutting processes in our detailed guide.
MIG/GMAW welding typically produces lower manganese fumes than SMAW or FCAW, but solid wire composition and shielding gas type influence the outcome. TIG/GTAW is generally the lowest manganese process because tungsten electrodes do not contain manganese, and filler rods can be specified as low-manganese variants. However, many Australian workshops default to standard high-manganese consumables for cost reasons, negating the inherent process advantage.
Health Effects of Manganese Exposure: Manganism and Neurological Damage
Manganism: Progressive Neurological Disease
Manganism is a chronic neurotoxic disorder resulting from cumulative occupational manganese inhalation. The condition develops insidiously over years or decades, with early symptoms often misattributed to fatigue, stress, or normal ageing. The characteristic progression mirrors Parkinson’s disease—tremor, rigidity, bradykinesia (slowness of movement), postural instability—but manganism-induced neurological damage is irreversible and progressive even after exposure ceases. Unlike Parkinson’s, which typically begins in one limb, manganism often presents with gait disturbance and psychiatric symptoms (mood changes, aggressive behaviour, anxiety). Learn more about MIG welding fumes assessment in our detailed guide.
The neurological damage occurs in the basal ganglia and substantia nigra, the same brain regions affected in Parkinson’s disease. Once manganese accumulates in these structures, the damage cannot be undone by treatment. This distinguishes manganism from reversible occupational diseases—workers cannot recover their neurological function even with complete exposure cessation and medical intervention. The International Agency for Research on Cancer (IARC) has not classified manganese as a carcinogen, but the neurological risk alone justifies rigorous exposure control.
Early Symptoms and Latency
Early manganism symptoms include tremor (often in the legs), muscle stiffness, mood disturbances, and cognitive changes such as memory problems and impaired concentration. Some workers report sleep disturbance, excessive salivation, or speech changes. These symptoms may appear subtle and are easily attributed to other causes, leading to diagnostic delay. The latency period—the time between exposure onset and symptom onset—varies from 5 to 20 years depending on exposure intensity and individual susceptibility. Young welders exposed to high manganese concentrations may develop symptoms in their 40s or 50s; those with lower cumulative exposure may not present until retirement age or later.
The insidious nature of manganism creates a liability exposure for Australian employers. A worker diagnosed with manganism 10 years after leaving a welding role may lodge a workers’ compensation claim. If the employer cannot demonstrate adequate exposure assessment and control, liability is substantial. Criminal liability under the WHS Act section 36 (officers’ due diligence) can also apply if an officer failed to ensure adequate health and safety management regarding manganese hazards.
Assessment: Air Monitoring and Biological Monitoring for Manganese
Air Monitoring Methodology
Air monitoring for manganese follows standard occupational hygiene protocols, but manganese-specific considerations apply. Personal inhalation zone sampling over an 8-hour shift provides the most relevant data for WES compliance. Stationary area sampling alone is insufficient because manganese concentrations vary dramatically with process, consumable, and worker position. A welder in a FCAW process 20 cm from the arc can inhale 0.3–0.5 mg/m³; the same worker at 1.5 m distance might inhale 0.05 mg/m³. This spatial variability means personal sampling is essential.
Sampling media for manganese typically include PVC (polyvinyl chloride) filters or cellulose ester filters with appropriate sampling pumps calibrated to 1.5–2.0 L/min. The sampling period should cover a full shift or full task cycle, not spot sampling. Manganese analysis is performed by inductively coupled plasma mass spectrometry (ICP-MS) or inductively coupled plasma optical emission spectrometry (ICP-OES) after acid digestion of the filter. Laboratory selection is critical: the laboratory must be accredited by NATA (National Association of Testing Authorities) for welding fume analysis to ensure quality assurance and defensibility of results.
Multiple sampling events are necessary to establish a representative exposure profile. Single-event sampling can be misleading if the day sampled involved unusually high or low fume generation. A minimum of 3–5 sampling days spread across different shifts, consumable batches, and seasonal conditions is recommended. For high-risk processes like FCAW, quarterly sampling is advised even after initial assessment establishes compliance, because consumable changes or process modifications can alter exposure.
{{IMAGE_BODY_2}}
Biological Monitoring: Blood Manganese Levels
Biological monitoring—measurement of manganese in blood or urine—complements air monitoring and reflects systemic manganese burden. Blood manganese concentration provides a biomarker of recent exposure and cumulative body burden. Normal (non-occupationally exposed) blood manganese ranges from 3 to 12 μg/L; occupationally exposed workers typically range from 10 to 50 μg/L depending on exposure intensity. Levels exceeding 50 μg/L warrant heightened concern and closer exposure assessment. Some occupational hygienists recommend biological action levels of 30 μg/L, above which more intensive controls are indicated.
However, biological monitoring alone cannot diagnose manganism. Elevated blood manganese indicates exposure and systemic burden but does not predict neurological outcomes. Conversely, normal blood manganese does not exclude neurological damage if past exposure was high; manganese accumulates preferentially in the brain, and blood levels may be misleadingly low while brain manganese is critically elevated. This means biological monitoring must be integrated with air monitoring, health surveillance (spirometry, questionnaire, physical examination), and medical assessment by an occupational physician.
Health Surveillance for Welders Exposed to Manganese
Baseline and Periodic Health Assessment
Health surveillance for manganese-exposed welders should commence before exposure begins (baseline assessment) and continue periodically throughout employment. Baseline assessment includes occupational and medical history, focused neurological examination assessing gait, tremor, rigidity, and cognitive function, and spirometry to establish baseline lung function (since welding fumes also affect respiratory health independent of manganese). Periodic surveillance—recommended annually for high-risk processes and every 2 years for moderate-risk processes—repeats neurological examination and spirometry to detect early signs of neurological decline or respiratory disease.
An occupational physician should conduct or supervise health surveillance. The physician should have familiarity with occupational neurotoxicology and manganism specifically. Generic occupational health services unfamiliar with manganism may miss early signs or fail to counsel workers appropriately. The outcome of health surveillance—any abnormal findings—must be communicated to the worker in understandable language, with explanation of implications and recommendations for further investigation if indicated.
Early Detection and Neurological Referral
Early detection of manganism requires high clinical suspicion. Subtle gait changes, personality changes, or tremor detected during periodic examination should trigger referral to a neurologist experienced in occupational neurotoxicology. Magnetic resonance imaging (MRI) of the brain may show characteristic T1 hyperintensity in the globus pallidus (manganese accumulation appears bright on T1-weighted sequences), supporting the diagnosis. However, MRI changes may precede clinical symptoms, making neuroimaging useful for early case identification. Workers with confirmed manganism should be removed from manganese exposure to prevent further neurological deterioration, even though existing damage cannot be reversed.
Control Strategies: The Hierarchy of Controls for Manganese
Elimination and Substitution
Elimination is not realistic for most welding operations; substitution is the primary control strategy. Low-manganese consumables are available but must be sourced intentionally and specified in procurement. Some electrode manufacturers produce low-manganese variants; examples include certain austenitic stainless steel electrodes designed for minimal manganese content and mild steel electrodes formulated with reduced manganese. Cost is typically 10–20% higher than standard consumables, but the health benefit justifies the investment. Process substitution also applies: choosing TIG welding over SMAW, or using low-manganese solid wire MIG over FCAW, reduces manganese exposure significantly.
Worksite trials with low-manganese consumables should be conducted before full implementation to verify weld quality, productivity, and processability. Some workers resist unfamiliar consumables, and weld properties may differ slightly; time must be allocated for transition and worker training. Once low-manganese consumables are introduced, air monitoring should verify that exposure has declined as expected.
Engineering Controls: Local Exhaust Ventilation
Local exhaust ventilation (LEV) for manganese processes is critical. A well-designed LEV system capturing fume at source can reduce manganese exposure by 50–80%. Extraction hoods, fume arms, and capture at the welding torch are standard LEV approaches. The system must be sized for the fume generation rate of the process: FCAW and SMAW require more aggressive LEV than MIG. Negative pressure at the hood and adequate hood placement (within 30 cm of the arc) are essential. LEV maintenance—filter cleaning, hood inspection, velocity verification—must be performed regularly. A poorly maintained LEV provides false reassurance and fails to protect workers.
For bench welding, stationary hood systems or articulating fume extraction arms are effective. For site welding (on-site construction), portable extraction or respiratory protection is often necessary because fixed LEV is impractical. The control hierarchy should not be bypassed: LEV is preferred over RPE, and RPE should supplement rather than replace LEV.
Administrative Controls and Personal Protective Equipment
Administrative controls include job rotation (reducing time per individual in high-manganese processes), worker training on manganese hazards and exposure avoidance, and monitoring of consumable usage to ensure low-manganese variants are actually being used. Personal protective equipment—respiratory protective equipment (RPE)—should be considered a supplementary control, not primary. Correctly fitted and maintained RPE can reduce inhaled manganese exposure, but RPE fit, compliance, and maintenance are often inadequate in real-world conditions. Half-mask APF 10 respirators are suitable for manganese if properly fitted; air-supplied respirators (supplied air at 25 L/min or higher, delivering fresh air continuously) are preferred for high-concentration environments or workers with facial hair precluding mask seal.
Table: Manganese Fume Generation and WES Compliance by Process
| Welding Process | Manganese Fume Generation (mg/min) | Typical Air Concentration (8-hr TWA, mg/mÂł) | WES Compliance Status | Primary Control Strategy |
|---|---|---|---|---|
| FCAW (high-Mn wire) | 15–25 | 0.25–0.45 | Exceeds WES | Low-Mn wire substitution + LEV |
| SMAW (high-tensile electrode) | 10–18 | 0.18–0.35 | Exceeds WES | Low-Mn electrode selection + LEV |
| SMAW (mild steel electrode) | 6–12 | 0.10–0.20 | Marginal/Exceeds WES | Low-Mn electrode + LEV |
| MIG/GMAW (solid wire) | 4–8 | 0.06–0.12 | Often exceeds WES | Wire type selection + LEV |
| TIG/GTAW (filler rod) | 2–5 | 0.03–0.08 | Likely compliant with controls | Low-Mn filler rod + LEV |
| SAW | 3–7 | 0.05–0.12 | Variable; high Mn concentration | Closed hood + LEV |
{{IMAGE_BODY_3}}
Note: Table shows illustrative ranges; actual exposure depends on process parameters, consumable composition, and ventilation. Air monitoring is essential to verify WES compliance for each worksite.
Frequently Asked Questions: Manganese in Welding Fumes
Is manganese exposure really as serious as cancer risk from stainless steel welding?
Yes, manganese neurotoxicity is equally serious, though the consequences differ. Stainless steel welding carries lung cancer risk (latency 15–40 years); manganese exposure carries neurological disease risk (latency 5–20 years). Manganism is irreversible and progressive, whereas some occupational cancers can be treated if detected early. A welder with manganism faces lifetime disability, cognitive decline, and loss of independence—consequences as severe as occupational cancer. Both hazards demand rigorous assessment and control.
Can workers recover from manganism if exposure stops?
No. Once manganese accumulates in the brain and neurological damage occurs, the damage is permanent. Stopping exposure prevents further accumulation and further decline, but does not reverse existing neurological injury. Early detection and exposure cessation can slow progression, but cannot restore lost neurological function. This underscores the importance of prevention—avoiding high exposure in the first place—rather than managing disease after onset.
How often should air monitoring for manganese be conducted?
Initial baseline monitoring should involve at least 3–5 sampling days across varying conditions to establish a representative exposure profile. Once baseline compliance is confirmed, annual monitoring is advisable for high-risk processes (FCAW, high-tensile SMAW); biennial monitoring for moderate-risk processes (standard SMAW, MIG). If consumables are changed, process modifications occur, or equipment maintenance is performed, repeat sampling should verify that exposure has not increased. Following any significant incident or worker health finding, immediate air monitoring is warranted.
What is the difference between air monitoring and biological monitoring for manganese?
Air monitoring measures manganese concentration in the breathing zone during a work shift (airborne exposure). Biological monitoring measures manganese in blood, reflecting the amount that has actually entered the body and systemic burden. Air monitoring shows what is in the air; biological monitoring shows what is in the body. Both are useful: air monitoring drives control improvements, and biological monitoring indicates effectiveness and worker body burden. Neither alone is sufficient; both should be integrated into a comprehensive assessment.
Are all manganese-containing electrodes and wires unsafe?
Manganese-containing consumables are standard in the welding industry because manganese improves weld deposit properties. The health risk arises from high-manganese formulations and cumulative inhalation exposure. Low-manganese alternatives exist and are safe if substituted systematically. The goal is not zero manganese (technically unrealistic) but reduced exposure to below the WES of 0.1 mg/mÂł through a combination of low-manganese consumable selection, engineering controls, and health surveillance.
What should I do if a worker is diagnosed with possible manganism?
Immediately cease the worker’s exposure to manganese (reassign to non-welding duties if possible, or if welding is unavoidable, provide enhanced controls such as supplied air respirators). Arrange urgent assessment by a neurologist experienced in occupational neurotoxicology; MRI brain imaging may be indicated. Notify the relevant regulator (SafeWork Authority in your state) and the worker’s insurer. Review air monitoring data and control measures across all manganese-exposed workers; if one case is identified, others may be at risk. Consider whether mandatory health surveillance for all manganese-exposed workers should be implemented. Consult legal advice regarding workers’ compensation and potential liability.
Conclusion: Manganese as a Critical Occupational Health Priority
Manganese in welding fumes represents a serious occupational health hazard in Australian workplaces, yet remains under-recognized and under-controlled in many facilities. The neurological consequences—irreversible manganism—are as severe as occupational cancer, with latency periods and cumulative exposure patterns that mean current welders are at risk of lifelong disability. The WES of 0.1 mg/m³ is stringent and challenging to meet with standard consumables and poor ventilation, but compliance is achievable through systematic substitution to low-manganese consumables, robust LEV design, and integrated health surveillance.
Australian PCBUs and safety managers must treat manganese assessment and control as a priority equal to chromium and nickel in stainless steel welding. Risk assessment must identify all manganese-exposed work groups, air monitoring must be conducted to establish baseline exposure and verify control effectiveness, and health surveillance must be implemented to detect early signs of neurological disease. Investment in low-manganese consumables, LEV systems, and occupational health services is a legal obligation under the WHS Act and a moral imperative to protect workers from preventable neurological harm.
